Skip navigation
Please use this identifier to cite or link to this item:
Files in This Item:
File Description SizeFormat 
ARTIGO_DevelopmentCharacterizationRecombinant.PDF1,14 MBAdobe PDFView/Open
Title: Development and characterization of recombinant antibody Fragments that recognize and neutralize in vitro Stx2 toxin from shiga toxin-producing escherichia coli
Authors: Luz, Daniela
Chen, Gang
Maranhão, Andrea Queiroz
Rocha, Leticia Barboza
Sidhu, Sachdev
Piazza, Roxane Maria Fontes
Assunto:: Anticorpos
Issue Date: Mar-2015
Publisher: Plos One
Citation: LUZ, Daniela et al. Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli. Plos One, v. 10, n.3, 2015. Diponível em: <>. Acesso em: 12 dez. 2016. doi:
Abstract: Background: Stx toxin is a member of the AB5 family of bacterial toxins: the active A subunit has N-glycosidase activity against 28S rRNA, resulting in inhibition of protein synthesis in eukaryotic cells, and the pentamer ligand B subunits (StxB) bind to globotria(tetra)osylceramide receptors (Gb3/Gb4) on the cell membrane. Shiga toxin-producing Escherichia coli strains (STEC) may produce Stx1 and/or Stx2 and variants. Strains carrying Stx2 are considered more virulent and related to the majority of outbreaks, besides being usually associated with hemolytic uremic syndrome in humans. The development of tools for the detection and/or neutralization of these toxins is a turning point for early diagnosis and therapeutics. Antibodies are an excellent paradigm for the design of high-affinity, protein-based binding reagents used for these purposes. Methods: and Findings In this work, we developed two recombinant antibodies; scFv fragments from mouse hybridomas and Fab fragments by phage display technology using a human synthetic antibody library. Both fragments showed high binding affinity to Stx2, and they were able to bind specifically to the GKIEFSKYNEDDTF region of the Stx2 B subunit and to neutralize in vitro the cytotoxicity of the toxin up to 80%. Furthermore, the scFv fragments showed 79% sensitivity and 100% specificity in detecting STEC strains by ELISA. Conclusion: In this work, we developed and characterized two recombinant antibodies against Stx2, as promising tools to be used in diagnosis or therapeutic approaches against STEC, and for the first time, we showed a human monovalent molecule, produced in bacteria, able to neutralize the cytotoxicity of Stx2 in vitro.
Licença:: Copyright: © 2015 Luz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Fonte: Acesso em: 12 dez. 2016.
Appears in Collections:CEL - Artigos publicados em periódicos

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/22422/statistics">

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.